SMC accepts MSD's KEYTRUDA®▼ (pembrolizumab) as monotherapy

MSD’s pembrolizumab approved by Scottish Medicines Consortium

The Scottish Medicines Consortium (SMC) has accepted MSD's KEYTRUDA®▼ (pembrolizumab) as monotherapy for the adjuvant treatment of adults with stage III melanoma with lymph...
Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment

Roche test detects antimicrobial resistance within TB

Roche has announced the CE-IVD launch of the cobas® MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA. This assay is part of the...
Army of NHS experts brought in to care homes to tackle over-medication

NHS experts band together to tackle ‘chemical cosh’ in care homes

An 'army' of health experts has been recruited by NHS England to help prevent care home residents being given too many medicines as charities...
State of the Discovery Nation published by MDC and BIA

State of the Discovery Nation report shares insights into UK medicines discovery industry

Medicines Discovery Catapult and the BioIndustry Association (BIA) have unveiled their 2019 State of the Discovery Nation report, providing new insights into the UK’s...
Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo

Bristol-Myers Squibb trial fails to meet primary endpoint

Bristol-Myers Squibb's Phase 3 CheckMate -498 trial evaluating Opdivo (nivolumab) plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated...
Symbicort reduces attacks in mild asthma

Sanofi’s Dupixent® ▼ (dupilumab) licensed in EU

Sanofi has announced that Dupixent® ▼ (dupilumab) has been licensed in the EU for the treatment of severe asthma with type 2 inflammation. The European...

Obesity an increasing factor in hospital admissions

Admissions to NHS hospitals, where obesity was recorded as either a primary or secondary diagnosis, increased by 15% (94,000) in 2017/18 compared to 2016/17. The...
AstraZeneca and Daiichi Sankyo announce positive top-line results for pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan

Pivotal Phase II DESTINY-Breast01 trial meets primary endpoint

AstraZeneca and Daiichi Sankyo have announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug conjugate...
competition to create Digital Innovation Hubs

MRC to run competition process for Digital Innovation Hubs

The MRC is to run a competition process on behalf of Health Data Research UK, to create Digital Innovation Hubs: centres of excellence dedicated...
State of the Discovery Nation published by MDC and BIA

Novartis announces results of MS Progression Discussion Tool

Novartis has announced results from a validation study of the algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscussTM. The tool aims to support...

Latest articles

GSK has announced changes to its sales representative incentive programme for representatives in certain countries

Changes to GSK sales representative incentive programme

GSK has announced changes to its sales representative incentive programme for representatives in certain countries. These changes reflect the growing shift in GSK’s portfolio...
UK's first free mental health app has gone live

Peer-to-peer mental health support app goes live

The UK's first free peer-to-peer mental health support app, 'Unmasked', has gone live after a period of extensive testing. The brainchild of three Yorkshiremen, Logan...
illegal market sharing over anti-nausea tablets

Drug firms accused of illegal market sharing over anti-nausea tablets

The Competitions and Markets Authority (CMA) has accused four pharmaceutical companies of illegal market sharing over anti-nausea tablets. The CMA has provisionally found that the pharmaceutical...

Popular articles

UK's first free mental health app has gone live

Peer-to-peer mental health support app goes live

The UK's first free peer-to-peer mental health support app, 'Unmasked', has gone live after a period of extensive testing. The brainchild of three Yorkshiremen, Logan...
NICE issues final guidance for Tegsedi ®▼

NICE issues final guidance for Tegsedi ®▼

Akcea Therapeutics UK Ltd, an affiliate of Akcea Therapeutics, Inc announced that the National Institute for Health and Care Excellence (NICE) has published its...
pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
GSK has announced changes to its sales representative incentive programme for representatives in certain countries

Changes to GSK sales representative incentive programme

GSK has announced changes to its sales representative incentive programme for representatives in certain countries. These changes reflect the growing shift in GSK’s portfolio...
Wasdell Group announces acquisition of Honeywood Limited

Wasdell Group expands portfolio with Honeywood acquisition

The Wasdell Group (Wasdell), a leading outsourcing partner for companies in the pharmaceutical industry, has announced its acquisition of Honeywood Limited, a specialist manufacturer...